Hikma Pharmaceuticals PLC
HKMPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $1 |
| % Growth | 6.4% | -0.7% | 8.4% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 43.7% | 42.3% | 48.2% | 47.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 15.6% | 16.8% | 22.4% | 8.4% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 14.4% | 8.5% | 14.4% | 4.1% |
| EPS | 1.08 | 0.6 | 1.02 | 0.26 |
| % Growth | 80% | -41.2% | 292.3% | – |
| EPS Diluted | 1.07 | 0.6 | 1.01 | 0.27 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 28.7% | 18.5% | 31.8% | 23.8% |